Ofev

SMC issues positive advice for treatment with Ofev® (nintedanib) for patients with chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILD)

The Scottish Medicines Consortium (SMC) has today announced that Ofev® (nintedanib) has been accepted for use by NHSScotland for the treatment of adult patients... Read More...

Healthcare Professional ONLY

This website is intended for Healthcare professionals only

Are you a qualified pharmacist or health professional?
By continuing to access this site, you are consenting to viewing promotional product information provided by our pharmaceutical company sponsors